UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

Journal of clinical oncology, 2011-02, Vol.29 (4), p.398-405

2011

Volltextzugriff (PDF)

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

Cancer chemotherapy and pharmacology, 2012-05, Vol.69 (5), p.1229-1240

2012

Volltextzugriff (PDF)

First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study

Journal of clinical oncology, 2005-02, Vol.23 (6), p.1178-1184

2005

Volltextzugriff (PDF)

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Journal of clinical oncology, 2002-02, Vol.20 (3), p.719-726

2002

Volltextzugriff (PDF)

Multiple receptor conversions during the course of metastatic breast cancer therapy: a case report and review of the literature

Journal of medical case reports, 2022-12, Vol.16 (1), p.461-461, Article 461

2022

Volltextzugriff (PDF)

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Journal of clinical oncology, 2003-08, Vol.21 (15), p.2889-2895

2003

Volltextzugriff (PDF)

Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer

Journal of clinical oncology, 2004-10, Vol.22 (19), p.3893-3901

2004

Volltextzugriff (PDF)

Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer

Journal of clinical oncology, 2001-11, Vol.19 (22), p.4216-4223

2001

Volltextzugriff (PDF)

High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: A retrospective chart review

Clinical therapeutics, 2009, Vol.31, p.2371-2378

2009

Volltextzugriff (PDF)

Toremifene for Breast Cancer: A Review of 20 Years of Data

Clinical breast cancer, 2014-02, Vol.14 (1), p.1-9

2014

Volltextzugriff (PDF)

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2 -Overexpressing Metastatic Breast Cancer

Journal of clinical oncology, 2023-03, Vol.41 (9), p.1638-1645

2023

Volltextzugriff (PDF)

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Journal of clinical oncology, 2023-03, Vol.41 (8), p.1501-1510

2023

Volltextzugriff (PDF)

Testing a positive-affect induction to reduce verbally induced nocebo hyperalgesia in an experimental pain paradigm

Pain (Amsterdam), 2019-10, Vol.160 (10), p.2290-2297

2019

Volltextzugriff (PDF)

Defining the Survival Benchmark for Breast Cancer Patients with Systemic Relapse

Breast Cancer: Basic and Clinical Research, 2015-01, Vol.2015 (2015), p.9-17

2015

Volltextzugriff (PDF)

Dual HER2-targeted approaches in HER2-positive breast cancer

Breast cancer research and treatment, 2012-01, Vol.131 (2), p.371-383

2012

Volltextzugriff (PDF)

Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients

Breast cancer research and treatment, 2019-07, Vol.176 (2), p.253-260

2019

Volltextzugriff (PDF)

When Can a Salvage Therapy (T-DM1) Take the Lead?

Journal of clinical oncology, 2016-10, Vol.34 (29), p.3492-3494

2016

Volltextzugriff (PDF)

Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature

Breast cancer research and treatment, 2015-10, Vol.153 (3), p.617-624

2015

Volltextzugriff (PDF)

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Journal of clinical oncology, 2002-02, Vol.20 (3), p.719-726

Vogel, C. L.

2002

Volltextzugriff (PDF)

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer

Cancer, 2014-09, Vol.120 (17), p.2657-2664

2014

Volltextzugriff (PDF)

First-Line Herceptin® Monotherapy in Metastatic Breast Cancer

Oncology, 2001-01, Vol.61 (Suppl 2), p.37-42

2001

Volltextzugriff (PDF)

Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

Cancer management and research, 2019-01, Vol.11, p.513-524

2019

Volltextzugriff (PDF)

Focused microwave phased array thermotherapy for primary breast cancer

Annals of surgical oncology, 2002-05, Vol.9 (4), p.326-332

2002

Volltextzugriff (PDF)

Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab

Clinical breast cancer, 2005-08, Vol.6 (3), p.240-246

2005

Volltextzugriff (PDF)

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Journal of clinical oncology, 1999-09, Vol.17 (9), p.2639-2648

1999

Volltextzugriff (PDF)

1 – 25 von 281

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(254)
Mit Volltextzugriff
(246)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

Multiple receptor conversions during the course of metastatic breast cancer therapy: a case report and review of the literature

Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm

Randomized Phase III Trial of Pegylated Liposomal Doxorubicin Versus Vinorelbine or Mitomycin C Plus Vinblastine in Women With Taxane-Refractory Advanced Breast Cancer

Multicenter Phase II Trial of Weekly Paclitaxel in Women With Metastatic Breast Cancer

High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: A retrospective chart review

Toremifene for Breast Cancer: A Review of 20 Years of Data

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2 -Overexpressing Metastatic Breast Cancer

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Testing a positive-affect induction to reduce verbally induced nocebo hyperalgesia in an experimental pain paradigm

Defining the Survival Benchmark for Breast Cancer Patients with Systemic Relapse

Dual HER2-targeted approaches in HER2-positive breast cancer

Vinorelbine plus Capecitabine (Vinocap): a retrospective analysis in heavily pretreated HER2 negative metastatic breast cancer patients

When Can a Salvage Therapy (T-DM1) Take the Lead?

Survival of patients with de-novo metastatic breast cancer: analysis of data from a large breast cancer-specific private practice, a university-based cancer center and review of the literature

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer

First-Line Herceptin® Monotherapy in Metastatic Breast Cancer

Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

Focused microwave phased array thermotherapy for primary breast cancer

Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with Trastuzumab

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

Suchergebnisse filtern